Skip to main content

Table 3 Previous and current treatment (nonNPSLE/NPSLE patients)

From: Altered white matter microstructure in lupus patients: a diffusion tensor imaging study

 

NonNPSLE patients (n = 25)

NPSLE patients (n = 39)

Fischer’s exact test

Previous treatment

 Glucocorticoids

23

34

0.278

 Antimalarials

26

36

0.219

 DMARDs

20

32

0.249

Current treatment

 Glucocorticoids

19

31

0.487

 Antimalarials

21

28

0.207

 DMARDs

16

23

0.446

 Cyclophosphamide

1

0

0.391

 MMF

4

11

0.207

 Azathioprin

10

10

0.175

 Rituximab

0

1

0.609

 IVIG

1

1

0.632

 Methotrexate

0

1

0.609

 Thalidomide

–

–

–

 Leukeran

–

–

–

 Belimimab

6

2

0.0034

 Antihypertensive treatment

7

13

0.435

 SSRI/SNRI

0

2

0.368

  1. There were no significant differences in previous or current treatment strategies between the groups, with the exception of current treatment of belimimab that was more frequent in the nonNPSLE subgroup
  2. NPSLE neuropsychiatric systemic lupus erythematosus, DMARD disease-modifying antirheumatic drug, MMF mycophenolate mofetil, IVIG intravenous immunoglobulins, SSRI/SNRI serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us